Comparative Pharmacology
Head-to-head clinical analysis: GANZYK RTU versus PREVYMIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANZYK RTU versus PREVYMIS.
GANZYK-RTU vs PREVYMIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine derivative that inhibits viral DNA synthesis by phosphorylation to ganciclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporation into viral DNA, causing chain termination.
Letermovir is an anti-cytomegalovirus (CMV) inhibitor that targets the CMV terminase complex, specifically the pUL56 subunit, thereby preventing cleavage and packaging of viral DNA into capsids, which inhibits viral replication.
5 mg/kg IV every 12 hours for 14-21 days.
480 mg orally once daily, with food.
None Documented
None Documented
Terminal elimination half-life approximately 3–4 hours in patients with normal renal function; prolonged to 10–24 hours in moderate to severe renal impairment (CrCl <50 mL/min), requiring dose adjustment.
Terminal elimination half-life is approximately 12 hours in healthy subjects, prolonged to ~19 hours in renal impairment (CrCl <30 mL/min).
Primarily renal via glomerular filtration and tubular secretion; >90% of dose excreted unchanged in urine; biliary/fecal elimination <5%.
Primarily excreted unchanged in feces via biliary secretion (93%), with renal excretion accounting for <2% of the dose.
Category C
Category C
Antiviral (CMV)
Antiviral (CMV)